The OPTIC trial studied the combination of IVIg and corticosteroids in patients with CIDP, showing improved disability compared to IVIg alone. While the trial was terminated early due to thromboembolic events in the combination arm, positive results were seen in multiple domains of improvement. The study’s findings suggest potential benefits of combination therapy in CIDP patients, with some clinicians considering adding steroids to current treatment regimens. Despite the setback, the study provides important insights for treating CIDP patients, guiding discussions on treatment options and potential risks. The results are considered clinically useful and may impact future treatment approaches for CIDP.
Source link
Combo Therapy for CIDP Benefits Despite Clotting Risk
